Scholarlink

Background <p>The majority of Parkinson’s disease (PD) patients experience motor fluctuations and dyskinesias as the disease progresses. Apomorphine has been used as an acute treatment for off episodes in PD in recent years. However, conclusions from clinical studies regarding the efficacy and safety of apomorphine have been inconsistent, particularly prior to the publication of larger pivotal trials.</p> Objectives <p>To systematically evaluate the efficacy and safety of apomorphine in PD patients, a meta-analysis of randomized controlled trials (RCTs) and single-armed studies were performed.</p> Methods <p>PubMed, Web of Science, Embase, and Cochrane databases were searched to identify all related studies. Outcomes of interest were changes in Parkinson’s Disease Rating Scale Part III (UPDRS-III) scores, ON and OFF time, and adverse events (AES).</p> Results <p>In this meta-analysis, 20 clinical studies were included (<i>n</i> = 1262 patients): seventeen RCTs, and three single-armed studies. The pooled results from RCTs indicate that apomorphine treatment significantly improved patients’ motor function compared to placebo. Specifically, there was a mean difference (MD) of -12.28 (95% CI: [-17.98, -6.59]) in UPDRS-III scores. Patients treated with apomorphine experienced a reduced off time (MD = -10.70, 95% CI: [-20.33, -1.06]), indicating a shorter duration of the “off” state. Furthermore, the combined results indicated a conversion rate from off to on state in PD patients treated with apomorphine of 0.79 (95% CI 0.67–0.89). In terms of safety analyses from single-armed studies, apomorphine treatment was associated with several AES, including nausea, drowsiness, vomiting, dizziness, and excessive sweating. However, the findings suggest that the incidence of AES was relatively low during treatment with apomorphine.</p> Conclusion <p>The meta-analysis results indicate that apomorphine effectively improves dyskinesia and motor fluctuations in patients with PD. Furthermore, the incidence of AES was relatively low during treatment with apomorphine.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Identification of the efficacy and safety of apomorphine in the treatment of Parkinson’s disease via meta-analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月27日

查看全文
  • Haidong Li,
  • Liwen Zhang,
  • Baona Jiang,
  • Lu Jing

摘要

Background

The majority of Parkinson’s disease (PD) patients experience motor fluctuations and dyskinesias as the disease progresses. Apomorphine has been used as an acute treatment for off episodes in PD in recent years. However, conclusions from clinical studies regarding the efficacy and safety of apomorphine have been inconsistent, particularly prior to the publication of larger pivotal trials.

Objectives

To systematically evaluate the efficacy and safety of apomorphine in PD patients, a meta-analysis of randomized controlled trials (RCTs) and single-armed studies were performed.

Methods

PubMed, Web of Science, Embase, and Cochrane databases were searched to identify all related studies. Outcomes of interest were changes in Parkinson’s Disease Rating Scale Part III (UPDRS-III) scores, ON and OFF time, and adverse events (AES).

Results

In this meta-analysis, 20 clinical studies were included (n = 1262 patients): seventeen RCTs, and three single-armed studies. The pooled results from RCTs indicate that apomorphine treatment significantly improved patients’ motor function compared to placebo. Specifically, there was a mean difference (MD) of -12.28 (95% CI: [-17.98, -6.59]) in UPDRS-III scores. Patients treated with apomorphine experienced a reduced off time (MD = -10.70, 95% CI: [-20.33, -1.06]), indicating a shorter duration of the “off” state. Furthermore, the combined results indicated a conversion rate from off to on state in PD patients treated with apomorphine of 0.79 (95% CI 0.67–0.89). In terms of safety analyses from single-armed studies, apomorphine treatment was associated with several AES, including nausea, drowsiness, vomiting, dizziness, and excessive sweating. However, the findings suggest that the incidence of AES was relatively low during treatment with apomorphine.

Conclusion

The meta-analysis results indicate that apomorphine effectively improves dyskinesia and motor fluctuations in patients with PD. Furthermore, the incidence of AES was relatively low during treatment with apomorphine.